4SC AG (FRA:VSC) Operating Margin %: -0.24% (As of Dec. 2025)


What is 4SC AG Operating Margin %?

4SC AG FRA:VSC Operating Margin % is -0.24% as of Dec. 2025. The stock has 7 warning signs investors should review.

Operating Margin % is calculated as Operating Income divided by its Revenue. 4SC AG's Operating Income for the six months ended in Dec. 2025 was €-0.01 Mil. 4SC AG's Revenue for the six months ended in Dec. 2025 was €2.55 Mil. Therefore, 4SC AG's Operating Margin % for the quarter that ended in Dec. 2025 was -0.24%.

Warning Sign:

4SC AG operating margin has been in a 5-year decline. The average rate of decline per year is -3.8%.

The historical rank and industry rank for 4SC AG's Operating Margin % or its related term are showing as below:

FRA:VSC' s Operating Margin % Range Over the Past 10 Years
Min: -3137.39   Med: -639.74   Max: -58.42
Current: -122.54


FRA:VSC's Operating Margin % is not ranked
in the Biotechnology industry.
Industry Median: -86.89 vs FRA:VSC: -122.54

4SC AG's 5-Year Average Operating Margin % Growth Rate was -3.80% per year.

4SC AG's Operating Income for the six months ended in Dec. 2025 was €-0.01 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 was €-3.17 Mil.

Warning Sign:

4SC AG has never been profitable in the past 3 years. It lost money every year.


4SC AG  (FRA:VSC) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


4SC AG Operating Margin % Related Terms


4SC AG Operating Margin % Historical Data

* Premium members only.

The historical data trend for 4SC AG's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4SC AG Operating Margin % Chart

4SC AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -58.42 -3,137.39 -2,771.71 -2,450.30 -122.54

4SC AG Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,045.76 -2,169.23 -2,782.47 -8,112.82 -0.24

FRA:VSC vs VRTX, REGN, ALNY: Operating Margin % Comparison

For the Biotechnology subindustry, 4SC AG's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


4SC AG Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 4SC AG's Operating Margin % distribution charts can be found below:

* The bar in red indicates where 4SC AG's Operating Margin % falls into.



4SC AG Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

4SC AG's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (A: Dec. 2025 ) / Revenue (A: Dec. 2025 )
=-3.17 / 2.587
=-122.54 %

4SC AG's Operating Margin % for the quarter that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2025 ) / Revenue (Q: Dec. 2025 )
=-0.006 / 2.548
=-0.24 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of -0.24% mean?
4SC AG (FRA:VSC) has a Operating Margin % of -0.24% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on 4SC AG and its competitors.
Is 4SC AG's Operating Margin % too high?
4SC AG's current Operating Margin % is -0.24%.
How does 4SC AG's Operating Margin % compare to VRTX and REGN?
4SC AG's Operating Margin % of -0.24% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on 4SC AG and its competitors. 4SC AG's current Operating Margin % is -0.24%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 4SC AG stock overvalued right now?
4SC AG (FRA:VSC) has a current Operating Margin % of -0.24%. The stock's GF Value™ is €3.51, compared to a current price of €0.10 — trading 97.2% below its estimated fair value. The current Operating Margin % is -0.24%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For 4SC AG (FRA:VSC), the current Operating Margin % is -0.24% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

4SC AG Business Description

Address Fraunhoferstrasse 22, Planegg-Martinsried, DEU, 82152
4SC AG is a clinical-stage biopharmaceutical company developing small-molecule drugs that can target key indications in cancer with high unmet medical needs. Its pipeline is protected by a comprehensive portfolio of patents and currently comprises two drug candidates in clinical development resminostat and Domatinostat. The geographic area of the company is Germany, the EU, and Other countries, and the majority of the revenue comes from Other Countries.